Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
Identifieur interne : 000F35 ( Istex/Curation ); précédent : 000F34; suivant : 000F36Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
Auteurs : Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-11.
English descriptors
- KwdEn :
Abstract
A 5‐year trial of ropinirole and levodopa in early Parkinson's disease showed that ropinirole is associated with reduced incidence of dyskinesias. This post hoc analysis investigated whether the dyskinesia‐sparing benefit of ropinirole is lost when levodopa is added to the regimen and evaluated other risk factors for developing dyskinesias. Patients receiving levodopa had a significantly higher risk of dyskinesias than those taking ropinirole monotherapy (hazard ratio [HR], 6.67; 95% confidence interval [CI], 3.23–14.29; P < 0.001). When patients randomized to ropinirole were treated with supplementary levodopa, the development of dyskinesias was not significantly different from that in those receiving levodopa from the start (HR, 0.80; 95% CI, 0.48–1.33; P = 0.39). However, the onset of dyskinesias was delayed by around 3 years compared with levodopa monotherapy. Adjusted analyses taking into account baseline and on‐treatment factors that influenced use of supplementary levodopa or the development of dyskinesias produced similar results. In conclusion, the risk of developing dyskinesias during maintained initial ropinirole monotherapy is very low. Only once levodopa is added does the risk substantially change. Early use of ropinirole postpones the onset of dyskinesias, but these benefits decline when levodopa therapy is started, with no evidence of a subsequent rapid “catch‐up” or a persisting preventive effect. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20988
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000F35
Links to Exploration step
ISTEX:BB8195542AFAD4DEAA1B2B80E3E692FA9AD193D5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Clinical Investigation Centre, Department of Pharmacology and INSERM U455, Toulouse Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, Department of Pharmacology and INSERM U455, Toulouse Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="1"><mods:affiliation>Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Faculty of Medicine, Imperial College, Hammersmith Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name><affiliation wicri:level="1"><mods:affiliation>Tel Aviv University Medical School, Tel Aviv, Israel</mods:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Tel Aviv University Medical School, Tel Aviv</wicri:regionArea></affiliation></author><author><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name><affiliation wicri:level="1"><mods:affiliation>Middelheim General Hospital, University of Antwerp, Antwerp, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Middelheim General Hospital, University of Antwerp, Antwerp</wicri:regionArea></affiliation></author><author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name><affiliation wicri:level="1"><mods:affiliation>University of Birmingham, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Birmingham, Birmingham</wicri:regionArea></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><mods:affiliation>Department of Medicine (Neurology) University of Toronto, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine (Neurology) University of Toronto, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Abdalla, Mona" sort="Abdalla, Mona" uniqKey="Abdalla M" first="Mona" last="Abdalla">Mona Abdalla</name><affiliation wicri:level="1"><mods:affiliation>London School of Hygiene and Tropical Medicine, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene and Tropical Medicine, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BB8195542AFAD4DEAA1B2B80E3E692FA9AD193D5</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20988</idno><idno type="url">https://api.istex.fr/document/BB8195542AFAD4DEAA1B2B80E3E692FA9AD193D5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F35</idno><idno type="wicri:Area/Istex/Curation">000F35</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Clinical Investigation Centre, Department of Pharmacology and INSERM U455, Toulouse Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, Department of Pharmacology and INSERM U455, Toulouse Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="1"><mods:affiliation>Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Faculty of Medicine, Imperial College, Hammersmith Hospital, London</wicri:regionArea></affiliation></author><author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name><affiliation wicri:level="1"><mods:affiliation>Tel Aviv University Medical School, Tel Aviv, Israel</mods:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Tel Aviv University Medical School, Tel Aviv</wicri:regionArea></affiliation></author><author><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name><affiliation wicri:level="1"><mods:affiliation>Middelheim General Hospital, University of Antwerp, Antwerp, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Middelheim General Hospital, University of Antwerp, Antwerp</wicri:regionArea></affiliation></author><author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name><affiliation wicri:level="1"><mods:affiliation>University of Birmingham, Birmingham, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Birmingham, Birmingham</wicri:regionArea></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><mods:affiliation>Department of Medicine (Neurology) University of Toronto, Toronto, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine (Neurology) University of Toronto, Toronto</wicri:regionArea></affiliation></author><author><name sortKey="Abdalla, Mona" sort="Abdalla, Mona" uniqKey="Abdalla M" first="Mona" last="Abdalla">Mona Abdalla</name><affiliation wicri:level="1"><mods:affiliation>London School of Hygiene and Tropical Medicine, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene and Tropical Medicine, London</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-11">2006-11</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1844">1844</biblScope><biblScope unit="page" to="1850">1850</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">BB8195542AFAD4DEAA1B2B80E3E692FA9AD193D5</idno><idno type="DOI">10.1002/mds.20988</idno><idno type="ArticleID">MDS20988</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dyskinesia</term><term>levodopa</term><term>ropinirole</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A 5‐year trial of ropinirole and levodopa in early Parkinson's disease showed that ropinirole is associated with reduced incidence of dyskinesias. This post hoc analysis investigated whether the dyskinesia‐sparing benefit of ropinirole is lost when levodopa is added to the regimen and evaluated other risk factors for developing dyskinesias. Patients receiving levodopa had a significantly higher risk of dyskinesias than those taking ropinirole monotherapy (hazard ratio [HR], 6.67; 95% confidence interval [CI], 3.23–14.29; P < 0.001). When patients randomized to ropinirole were treated with supplementary levodopa, the development of dyskinesias was not significantly different from that in those receiving levodopa from the start (HR, 0.80; 95% CI, 0.48–1.33; P = 0.39). However, the onset of dyskinesias was delayed by around 3 years compared with levodopa monotherapy. Adjusted analyses taking into account baseline and on‐treatment factors that influenced use of supplementary levodopa or the development of dyskinesias produced similar results. In conclusion, the risk of developing dyskinesias during maintained initial ropinirole monotherapy is very low. Only once levodopa is added does the risk substantially change. Early use of ropinirole postpones the onset of dyskinesias, but these benefits decline when levodopa therapy is started, with no evidence of a subsequent rapid “catch‐up” or a persisting preventive effect. © 2006 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000F35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:BB8195542AFAD4DEAA1B2B80E3E692FA9AD193D5
|texte= Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
}}
| This area was generated with Dilib version V0.6.23. |  |